ArticleOncoimmunology
Subgroup-specific immune and stromal microenvironment in medulloblastoma.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Outcomes of immunotherapy in medulloblastoma: a systematic review.The oncologist · 2026Pooled it
- From developmental origins to relapse: molecular and therapeutic insights in medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Review
- New developments and prospects for drug delivery in medulloblastoma.Molecular therapy. Oncology · 2026Review
- MIF-CD74 signaling drives immune modulation in medulloblastoma.Neuro-oncology · 2026Article
- Profiling T-cell activity and exclusion in pediatric medulloblastoma highlights immunotherapy-responsive subgroups.Journal of neuro-oncology · 2026Article
- Decoding the immune microenvironment: precision immunotherapy for medulloblastoma subtypes.Frontiers in immunology · 2026Review
- Integrin β1 signaling at the crossroads of cellular plasticity, the tumor microenvironment, and therapy resistance in medulloblastoma.Frontiers in oncology · 2026Review
- Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments.Frontiers in oncology · 2026Review
- Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies.Frontiers in oncology · 2026Review
- EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity.Oncoimmunology · 2025Article
- Advancing Medulloblastoma Therapy in Pediatrics: Integrative Molecular Classification and Emerging Treatments.Brain sciences · 2025Review
- Article
- Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression.Journal for immunotherapy of cancer · 2025Article
- Characterization of immune microenvironment associated with medulloblastoma metastasis based on explainable machine learning.Pediatric investigation · 2025Article
- Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.Nature communications · 2025Article
- The Role of Chronic Inflammation in Pediatric Cancer.Cancers · 2025Review
- Tumor-associated macrophages correlate with better outcome in SHH medulloblastoma.Frontiers in oncology · 2025Article
- Medulloblastoma: biology and immunotherapy.Frontiers in immunology · 2025Review
- CD4 T cells correlate with better prognosis in medulloblastoma.Frontiers in oncology · 2025Article
- Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma.Genome medicine · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knowledge on immune and stromal cells in medulloblastoma microenvironment is still limited as previous work was frequently restricted by low sample size and the lack of molecular subgroup information. We characterized 10 microenvironment cell populations as well as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.